Carl Zeiss Meditec AGXSWX:AFX 70 EV-to-EBIT is 13.97 as of Jul. 12, 2026, which is 46% below its 10-year median of 25.68. GuruFocus rates XSWX:AFX with a GF Score™ of 70/100 and a GF Value™ of CHF62.89 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 464 Medical Devices & Instruments companies, Carl Zeiss Meditec AG ranks better than 65.09% on this metric.
The historical rank and industry rank for Carl Zeiss Meditec AG's EV-to-EBIT or its related term are showing as below:
XSWX:AFX'
s EV-to-EBIT Range Over the Past 10 Years
Min: 9.83 Med: 25.68 Max: 57.8
Current: 14.29
During the past 13 years, the highest EV-to-EBIT of Carl Zeiss Meditec AG was 57.80. The lowest was 9.83. And the median was 25.68.
XSWX:AFX's EV-to-EBIT is ranked better than 65.09% of 464
companies
in the Medical Devices & Instruments industry
Industry Median: 18.34
vs XSWX:AFX: 14.29
Carl Zeiss Meditec AG (XSWX:AFX) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Carl Zeiss Meditec AG's Enterprise Value for the quarter that ended in Dec. 2025 was CHF0 Mil.
Carl Zeiss Meditec AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF184 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:AFX vs ISRG, BDX, MDLN: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, Carl Zeiss Meditec AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carl Zeiss Meditec AG EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Carl Zeiss Meditec AG's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Carl Zeiss Meditec AG's EV-to-EBIT falls into.
Carl Zeiss Meditec AG's current Enterprise Value is CHF2,576 Mil.
Carl Zeiss Meditec AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF184 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carl Zeiss Meditec AG (XSWX:AFX) has a EV-to-EBIT of 13.97 as of Jul. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Carl Zeiss Meditec AG and its competitors. This is 46% below median its historical median of 25.68. Over the past decade, Carl Zeiss Meditec AG's EV-to-EBIT has ranged from 9.83 to 57.80. According to the industry distribution chart, Carl Zeiss Meditec AG ranks #162 out of 464 companies in the Medical Devices & Instruments industry, placing it in the top 34.9%.
Is Carl Zeiss Meditec AG's EV-to-EBIT too high?
Carl Zeiss Meditec AG's current EV-to-EBIT of 13.97 is 46% below median its 10-year median of 25.68. Over the past 10 years, this metric has ranged from a low of 9.83 to a high of 57.80. The Medical Devices & Instruments industry median EV-to-EBIT is 18.34. Carl Zeiss Meditec AG's value of 13.97 is 23.8% below this industry median. Based on the distribution chart, Carl Zeiss Meditec AG ranks #162 out of 464 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Carl Zeiss Meditec AG has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Carl Zeiss Meditec AG's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Carl Zeiss Meditec AG ranks #162 out of 464 companies for EV-to-EBIT. This puts Carl Zeiss Meditec AG in the upper half of its industry. The industry median EV-to-EBIT is 18.34. Carl Zeiss Meditec AG's value of 13.97 is 23.8% below this benchmark. Historically, Carl Zeiss Meditec AG's own EV-to-EBIT has ranged from 9.83 to 57.80 over the past decade. While the company's 10-year median is 25.68 vs. the industry median of 18.34, Carl Zeiss Meditec AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.34, based on 464 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carl Zeiss Meditec AG's current EV-to-EBIT of 13.97 is 23.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Carl Zeiss Meditec AG and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carl Zeiss Meditec AG's current EV-to-EBIT is 13.97, which is 46% below median its own 10-year median of 25.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carl Zeiss Meditec AG stock overvalued right now?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG (XSWX:AFX) is currently considered Significantly Undervalued. The stock's GF Value™ is CHF62.89, compared to a current price of CHF26.30 — trading 58.2% below its estimated fair value. The current EV-to-EBIT is 13.97, which is 46% below median its 10-year median of 25.68 and 23.8% below the Medical Devices & Instruments industry median of 18.34. Carl Zeiss Meditec AG's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Carl Zeiss Meditec AG (XSWX:AFX), the current EV-to-EBIT is 13.97 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?
Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued.
The current stock price of CHF26.30 is trading 58.2% below its estimated GF Value™ of CHF62.89.
GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.
Key valuation signals for XSWX:AFX:
EV-to-EBIT: 13.97 (46% below median its 10-year median of 25.68)
GF Value™: CHF62.89 vs. price of CHF26.30 (58.2% below fair value)
Industry Position: 23.8% below the Medical Devices & Instruments median (#162 of 464)
No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
70GF Score
Get the complete analysis for XSWX:AFX
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:AFX has been successfully added to your 
